Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study

Laetitia E Lamberts, Maximillian Koch, Johannes S de Jong, Arthur Adams, Juergen Glatz, Marriette E G Kranendonk, Anton G T Terwisscha van Scheltinga, Liesbeth Jansen, Jakob de Vries, Marjolijn N Lub-de Hooge, Carolien P Schröder, Annelies Jorritsma-Smit, Matthijs D Linssen, Esther Boer, de, Bert van der Vegt, Wouter B Nagengast, Sjoerd G Elias, Sabrina Oliveira, Arjen Witkamp, Willem P Th M MaliElsken van der Wall, Paul J Van Diest, Elisabeth G de Vries, Vasilis Ntziachristos, Gooitzen M van Dam*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

132 Citations (Scopus)
535 Downloads (Pure)


PURPOSE: to provide proof of principle of safety, breast tumor-specific uptake and positive tumor margin assessment of the systemically administered near-infrared fluorescent (NIRF) tracer bevacizumab-IRDye800CW targeting vascular endothelial growth factor (VEGF)-A in breast cancer patients.

EXPERIMENTAL DESIGN: Twenty patients with primary invasive breast cancer eligible for primary surgery received 4.5 mg bevacizumab-IRDye800CW as intravenous bolus injection. Safety aspects were assessed as well as tracer uptake and tumor delineation during surgery and ex vivo in surgical specimens using an optical imaging system. Ex vivo multiplexed histopathology analyses were performed for evaluation of biodistribution of tracer uptake and co-registration of tumor tissue and healthy tissue.

RESULTS: None of the patients experienced adverse events. Tracer levels in primary tumor tissue were higher compared to those in the tumor margin (P < 0.05) and healthy tissue (P < 0.0001). VEGF-A tumor levels also correlated with tracer levels (r = 0.63, P < 0.0002). All but one tumor showed specific tracer uptake. Two out of 20 surgically excised lumps contained microscopic positive margins detected ex vivo by fluorescent macro- and microscopy and confirmed at the cellular level.

CONCLUSIONS: Our study shows that systemic administration of the bevacizumab-IRDye800CW tracer is safe for breast cancer guidance and confirms tumor and tumor-margin uptake as evaluated by a systematic validation methodology. The findings are a step towards a phase II dose-finding study aimed at in vivo margin assessment and point to a novel drug assessment tool that provides a detailed picture of drug distribution in tumor tissue.

Original languageEnglish
Pages (from-to)2730-2741
Number of pages12
JournalClinical Cancer Research
Issue number11
Publication statusPublished - 1-Jun-2017



Cite this